The invention relates to cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]-decan-2-one derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Video and audio recordings; films; compact discs; DVDs; CD ROMs; computer software; computer software and publications in electronic form (also downloadable); all the aforesaid goods relating to medical, pharmaceutical, healthcare and life-style matters. Printed matter; publications, instructional and teaching materials; plastic materials for packaging. Education; providing of training; arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums and workshops in the field of pain science and medicine; publication of books, texts and leaflets; production, distribution and rental of videos, films, audio recordings and compact discs, all relating to medical, pharmaceutical, healthcare and life-style matters. Scientific and technological services and research relating thereto, more specifically in the field of pain; biological research; pharmaceutical research and development; product quality evaluation and drug development; design and development of computer hardware and software. Medical services; informatory, advisory and consultancy services relating to medical, pharmaceutical and healthcare matters and disease prevention.
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Video and audio recordings; films; compact discs; DVDs; CD ROMs; computer software; computer software and publications in electronic form (also downloadable); all the aforesaid goods relating to medical, pharmaceutical, healthcare and life-style matters. Printed matter; publications, instructional and teaching materials; plastic materials for packaging. Education; providing of training; arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums and workshops in the field of pain science and medicine; publication of books, texts and leaflets; production, distribution and rental of videos, films, audio recordings and compact discs, all relating to medical, pharmaceutical, healthcare and life-style matters. Scientific and technological services and research relating thereto, more specifically in the field of pain; biological research; pharmaceutical research and development; product quality evaluation and drug development; design and development of computer hardware and software. Medical services; informatory, advisory and consultancy services relating to medical, pharmaceutical and healthcare matters and disease prevention.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely, pharmaceutical preparations for the treatment of osteoarthritis, rheumatoid arthritis, diabetic neuropathy, peripheral neuropathy, small fiber neuropathy, trigeminal neuralgia, post herpetic neuralgia, post amputation neuropathic pain, post operative pain, cancer-related pain, trigger point pain, sciatica, overactive bladder syndrome, fibromyalgia syndrome, erythromelalgia; medical preparations for the treatment of pain; sanitary preparations for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely, pharmaceutical preparations for the treatment of osteoarthritis, rheumatoid arthritis, diabetic neuropathy, peripheral neuropathy, small fiber neuropathy, trigeminal neuralgia, post herpetic neuralgia, post amputation neuropathic pain, post operative pain, cancer-related pain, trigger point pain, sciatica, overactive bladder syndrome, fibromyalgia syndrome, erythromelalgia; medical preparations for the treatment of pain; sanitary preparations for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
38 - Telecommunications services
40 - Treatment of materials; recycling, air and water treatment,
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; hygienic preparation for medical purposes; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings. Software applications for computer and mobile devices; scientific, weighing, measuring, signaling, checking (supervision) apparatus and instruments; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, data processing equipment and computers. Printed teaching and training materials in the field of medicine, in the field of pharmaceuticals and in the field of healthcare products for doctors and pharmacists. Preparation and staging of exhibitions for commercial and promotional purposes in the medical and pharmaceutical field and for pharmaceutical manufacturers, pharmacists, physicians, patients, health insurance companies and their associations; provision of business and commercial information on the Internet with respect to medicines and pharmaceuticals. Providing online chat rooms for transmission of messages among computer users in the field of pharmaceutical and medical developments. Manufacturing of pharmaceutical and healthcare products. Training with respect to medicine and pharmaceutical therapy; publication of books and journals; organizing and conducting of seminars and congresses, including working groups and research groups in the medical and pharmaceutical field for pharmaceutical manufacturers, pharmacists, physicians, health insurance companies and their associations. Scientific and technical research work in the medical and pharmaceutical field including conducting clinical trials of pharmaceutical products, especially for pharmaceutical manufacturers, pharmacists, physicians, health insurance companies and their associations. Medical services.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
38 - Telecommunications services
40 - Treatment of materials; recycling, air and water treatment,
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations; hygienic preparation for medical purposes; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings. Software applications for computer and mobile devices; scientific, weighing, measuring, signaling, checking (supervision) apparatus and instruments; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, data processing equipment and computers. Printed teaching and training materials in the field of medicine, in the field of pharmaceuticals and in the field of healthcare products for doctors and pharmacists. Preparation and staging of exhibitions for commercial and promotional purposes in the medical and pharmaceutical field and for pharmaceutical manufacturers, pharmacists, physicians, patients, health insurance companies and their associations; provision of business and commercial information on the Internet with respect to medicines and pharmaceuticals. Providing online chat rooms for transmission of messages among computer users in the field of pharmaceutical and medical developments. Manufacturing of pharmaceutical and healthcare products. Training with respect to medicine and pharmaceutical therapy; publication of books and journals; organizing and conducting of seminars and congresses, including working groups and research groups in the medical and pharmaceutical field for pharmaceutical manufacturers, pharmacists, physicians, health insurance companies and their associations. Scientific and technical research work in the medical and pharmaceutical field including conducting clinical trials of pharmaceutical products, especially for pharmaceutical manufacturers, pharmacists, physicians, health insurance companies and their associations. Medical services.
The present invention relates to compounds according to general formula (I) which act as inhibitors of NaV1.8 and can be used in the treatment of pain.
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 231/20 - One oxygen atom attached in position 3 or 5
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
28.
TOPICAL CAPSAICINOIDS FOR TREATING A NEUROPATHIC CONDITION IN COVID-19 PATIENTS
The invention relates to one or more high-concentration capsaicinoid topical dose units for use in the treatment of a neuropathic condition, preferably neuropathic pain, in a patient who is or who was previously infected with a coronavirus, wherein each of said one or more high-concentration capsaicinoid topical dose units contains capsaicinoid, preferably capsaicin, at a concentration of at least 5 wt.-%, relative to the total weight of the dose unit.
The invention relates to a pharmaceutical dosage form comprising Tapentadol or a physiologically ac- ceptable salt thereof for use in the treatment of pain in a patient who is or who was previously infected with a coronavirus.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Sanitary preparations for medical purposes; Pharmaceuticals, namely, pharmaceutical preparations for the treatment of osteoarthritis, rheumatoid arthritis, diabetic neuropathy, peripheral neuropathy, small fibre neuropathy, trigeminal neuralgia, post herpetic neuralgia, post amputation neuropathic pain, post operative pain, cancer-related pain, trigger point pain, sciatica, overactive bladder syndrome, fibromyalgia syndrome, erythromelalgia; Medical preparations for the treatment of pain
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Sanitary preparations for medical purposes; Pharmaceuticals, namely, pharmaceutical preparations for the treatment of osteoarthritis, rheumatoid arthritis, diabetic neuropathy, peripheral neuropathy, small fibre neuropathy, trigeminal neuralgia, post herpetic neuralgia, post amputation neuropathic pain, post operative pain, cancer-related pain, trigger point pain, sciatica, overactive bladder syndrome, fibromyalgia syndrome, erythromelalgia; Medical preparations for the treatment of pain
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
38 - Telecommunications services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable software for computers and mobile devices for measuring, monitoring, recording, displaying and transmitting information relating to patients' health in the field of pain treatment. Data processing, systematisation and management, being provision of a web- and app based tool for tracking and visualizing data in the field of pain treatment. Computer and technology services for securing and exchanging data accessible via telecommunication networks applied to the healthcare field of pain treatment. Supplying temporarily use of web-based software in the field of pain treatment; Maintenance and updating of software in the field of pain treatment. Providing information in the healthcare field of pain treatment; providing website portals on the internet featuring information in the healthcare field of pain treatment; providing content retrievable via the internet in the nature of providing information in the healthcare field of pain treatment.
The invention relates to a tablet which provides a sustained release of tapentadol, the tapentadol being contained in the form of a salt with tartaric acid, in particular in the form of a salt with L-(+)-tartaric acid. The tablet has satisfactory mechanical properties, e.g. in terms of its breaking strength and friability, and can be produced under considerably simplified tableting conditions, in particular at reduced pressing force.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Sanitary preparations for medical purposes; Pharmaceuticals, namely, pharmaceutical preparations for the treatment of osteoarthritis, rheumatoid arthritis, diabetic neuropathy, peripheral neuropathy, small fibre neuropathy, trigeminal neuralgia, post herpetic neuralgia, post amputation neuropathic pain, post operative pain, cancer-related pain, trigger point pain, sciatica, overactive bladder syndrome, fibromyalgia syndrome, erythromelalgia; Medical preparations for the treatment of pain
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Sanitary preparations for medical purposes; Pharmaceuticals, namely, pharmaceutical preparations for the treatment of osteoarthritis, rheumatoid arthritis, diabetic neuropathy, peripheral neuropathy, small fibre neuropathy, trigeminal neuralgia, post herpetic neuralgia, post amputation neuropathic pain, post operative pain, cancer-related pain, trigger point pain, sciatica, overactive bladder syndrome, fibromyalgia syndrome, erythromelalgia; Medical preparations for the treatment of pain
49.
KIT COMPOSED OF A TWO-COMPONENT TISSUE ADHESIVE AND A TEXTILE STRUCTURE FOR STRENGTHENING THE CONNECTIVE TISSUE AFTER AN OPERATION, AND USE THEREOF
The present invention relates to a mesh implantation system in the field of hernia surgery, said system comprising a textile fabric and a tissue adhesive, wherein the textile fabric is composed of a polymer selected from the group comprising or consisting of polyethersulphones, polysulphones, polyolefins, polyesters, fluoropolymers, silicones or mixed polymers and/or mixtures thereof, wherein the system is characterised in that the fabric adhesive is a two-component adhesive having as a first component at least one amino-functional aspartic acid ester acting as a curing agent and having as a second component an isocyanate-functional prepolymer. The invention also relates to: a planar composite material suitable for use as a mesh implant in the field of hernia surgery, obtained or obtainable from the aforementioned system; a method for producing such a planar composite material; and a mesh implantation method in the field of hernia surgery using such a system.
The invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to an oral pharmaceutical dosage form comprising a multitude of particles, wherein the particles comprise a pharmacologically active ingredient at a content within the range of from 5.0 to 65 wt.-%, (b) an EVA copolymer at a content within the range of from 25 to 85 wt.-%, and (c) an additional excipient at a content within the range of from 8.0 to 30 wt.-%, in each case relative to the total weight of the particles. The pharmacologically active ingredient is embedded in a prolonged release matrix comprising the EVA copolymer and the additional excipient. The pharmaceutical dosage form preferably provides resistance against solvent extraction, resistance against grinding, and resistance against alcoholic dose-dumping.
The invention relates to an oral pharmaceutical dosage form comprising a multitude of particles, wherein the particles comprise (a) a pharmacologically active ingredient; (b) an EVA copolymer having a vinylacetate content within the range of from 5.0 to 50 wt.-%, relative to the total weight of the EVA copolymer; (c) a gliding agent; and (d) an additional excipient; wherein the pharmacologically active ingredient is embedded in a prolonged release matrix comprising the EVA copolymer, the gliding agent and the additional excipient.
The invention relates to a regimen for repeated treatment of a neuropathic condition, preferably peripheral neuropathic pain, comprising a first application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches, followed by a second application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches, wherein the time period between the first application and the second application is preferably shortened in order to increase the responder rate.
The invention relates to a scored tablet comprising Tapentadol or a physiologically acceptable salt thereof embedded in a prolonged release matrix material; wherein the scored tablet provides prolonged release of Tapentadol or the physiologically acceptable salt thereof; wherein the scored tablet has a site of mechanical weakness along which it can be manually broken into two separate halves preferably having essentially the same size, shape and weight; and wherein the in vitro release profile of the scored tablet essentially corresponds to the in vitro release profile of each of the two separate halves. The invention further relates to a process for the preparation of such a scored tablet.
The invention relates to repeated treatment of a neuropathic condition, preferably peripheral neuropathic pain, by application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches, to patients who previously did not respond or insufficiently responded to a previous application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches or any other high-concentration capsaicin and/or capsaicinoid formulation previously topically administered.
The invention relates to a pharmaceutical dosage form providing prolonged release of Tapentadol, wherein Tapentadol is present in form of a salt with phosphoric acid (orthophosphoric acid), preferably as dihydrogenphosphate salt. The dosage form according to the invention provides improved prolonged release properties, is particularly resistant against ethanol induced dose dumping, and beyond such resistance provides additional safety features with regard to concomitant use of ethanol, e.g. alcoholic beverages.
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
The present invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
The present invention relates to a layered construction for staunching a bleed or the emission of tissue fluid from a wound, comprising a tissue adhesive layer composed of an at least two-component tissue adhesive system and/or reaction products thereof, and also to a protective liner applied thereto and at least partly covering the tissue adhesive layer, said liner comprising a polymer film that is not nonstick-coated; the tissue adhesive system comprising at least one amino-functional aspartic ester as curing agent with optionally at least one filler as first component, and as second component an isocyanate-functional prepolymer, where the layered construction is characterized in that the polymer component of the polymer film is selected from thermoplastic polymers and the polymer film relative to the cured tissue adhesive system has a peel force in the roller peel test according to DIN EN 1464 – 2010 – 06 of less than 2.5 N/cm. The invention also relates to a method for staunching a bleed or the emission of tissue fluid from a wound, to a kit for such a method, and to the use of a polymer film that is not nonstick-coated as a protective liner for an at least two-component tissue adhesive system.
The invention relates to a metering system (1) for a tissue adhesive system which comprises at least two components, comprising a container which is divided into a first chamber (2) and a second chamber (3) in the longitudinal direction, said container having a rigidly designed shoulder piece (5) in the region of the first chamber (2), which is arranged on the container outlet (4). The first chamber (2) contains a film bag (6) for receiving the first component of the tissue adhesive system, and the remaining cavity of the container body, as the second chamber (3), is designed to receive the second component of the tissue adhesive system and is surrounded by a flexible container casing (7). A guide channel (8) extends from the container outlet (4) into the second chamber (3), and a mixing tube (9) with an inner static mixer is arranged in the guide channel in a longitudinally movable manner. The mixing tube (9) within the guide channel (8) can be pulled out of the container outlet (4) in the longitudinal direction at least to such a degree that an outlet opening (10), which is provided in the guide channel (8) in the region of the first chamber (2), is released in order to bring the first component of the tissue adhesive system into contact with the second component of the tissue adhesive system in the guide channel (8). The invention additionally relates to a kit consisting of a metering system which is filled with a tissue adhesive system comprising at least two components and to a method for closing a wound using such a kit.
The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
Goods & Services
Information for educational purposes in the field of medicine stored on electronic data carriers; Data carriers containing instructional and reference stored works with text and/or audio material and/or image material and/or film material for educational purposes in the field of medicine; electronic and digital publications in the field of medicine (downloadable); software (downloadable) to enable access to data and information for educational purposes in the field of medicine. Books of all types, in particular reference works; Printed matter and published material; all the aforementioned goods in the field of medicine. Publication of books and electronic data media; providing of electronic publications via the internet and electronic media and through the publication of published material and printed matter; Publication of printed matter via the Internet and electronic media; all the aforementioned services in the field of medicine.
The present invention relates to a dosing system (1) having at least two chambers (2, 3) for a fabric adhesive system comprising at least two components. A first chamber (2) takes the form of a hollow cylinder (H) which is closed at one end face (2a) and open at the opposite end face (2b). A second chamber (3) takes the form of an annular gap (4) in a solid cylinder (V), said annular gap extending from an end face (3a) facing the hollow cylinder (H) to a mixing chamber (5) situated at the opposite end (3b) of the solid cylinder (V). A feed channel (6) is provided which extends on the inside of the annular gap (4) in the solid cylinder (V) from the end face (3a) of the solid cylinder (V) facing the hollow cylinder (H) into the mixing chamber (5), wherein a mixing tube (7) protrudes laterally out of the mixing chamber (5) and is arranged displaceably transversely to the longitudinal extent of the solid cylinder (V).
The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention relates to a synergistic pharmaceutical combination containing tramadol hydrochloride and pregabalin at a w/w ratio of between 1:1.5 and 1:2.5 and pharmaceutically acceptable excipients, said synergistic combination having an oral and parenteral pharmaceutical dosage form. The present invention also relates to methods for treating neuropathic pain, where said neuropathic pain can be of the central or peripheral type inter alia, and to the use of the synergistic pharmaceutical combination for the treatment of neuropathic pain.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
A61P 25/04 - Centrally acting analgesics, e.g. opioids
70.
SYNERGISTIC PHARMACEUTICAL COMBINATION COMPRISING TRAMADOL HYDROCHLORIDE AND PREGABALIN, AND USE THEREOF FOR THE TREATMENT OF NEUROPATHIC PAIN
The invention relates to a synergistic pharmaceutical combination containing tramadol hydrochloride and pregabalin at a w/w ratio of between 1:1.5 and 1:2.5 and pharmaceutically acceptable excipients, said synergistic combination having an oral and parenteral pharmaceutical dosage form. The present invention also relates to methods for treating neuropathic pain, where said neuropathic pain can be of the central or peripheral type inter alia, and to the synergistic pharmaceutical combination for use in the treatment of neuropathic pain.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
A61P 25/04 - Centrally acting analgesics, e.g. opioids
71.
Medical adhesives for stopping heavy bleeding and sealing leakages
The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I)
applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.
A method for carrying out structured rehabilitation, comprising providing (52) a mobile appliance for a patient; repeatedly retrieving (54, 60) status information items relating to the patient by the mobile appliance before and/or after an endoprosthetic intervention; wherein the status information items to be retrieved comprise pain values and wherein repeatedly retrieving (54, 60) the status information items comprises the mobile appliance repeatedly requesting (58) the patient to specify a pain value corresponding to a current subjectively perceived pain in each case, transmitting (70) the status information items to a server; analyzing (72) the status information items by means of the server; and outputting (76) a message on the basis of the result of the analysis (72) of the status information items.
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
73.
COMPOSITION FOR TREATING URINARY FREQUENCY AND/OR URINARY URGENCY
EE)-4-(3-fluorophenyl)-2',3',4',9'- tetrahydro-N,N-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1'[1H]-pyrido[3,4-b]indol]-4- amine for use in the treatment of urinary frequency and/or urinary urgency. The pharmaceutical composition is suitable for topical administration, especially for intravesical administration.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
The invention relates to neridronic acid for use of in a method of treating complex regional pain syndrome (CRPS) or pain associated with CRPS, wherein neridronic acid is administered intravenously in one or more individual unit doses each being administered for at least 4 hours. The invention relates further to neridronic acid for use in a method of treating CRPS according to the duration of CRPS in the patient, to a particular dosing according to renal functionality of the patient and to a kit for the administration of neridronic acid in the inventive methods.
The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 211/76 - Oxygen atoms attached in position 2 or 6
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
79.
TAMPER RESISTANT FORMULATION OF EPHEDRINE AND ITS DERIVATIVES COMPRISING A CONVERSION INHIBITOR
The invention relates to a pharmaceutical dosage form having a breaking strength of at least 300 N and comprising (i) an ephedrine component selected from the group consisting of ephedrine, pseudoephedrine and the physiologically acceptable salts thereof, wherein preferably the weight content of the ephedrine component is within the range of from 0.1 to 60 wt.-%, relative to the total weight of the pharmaceutical dosage form; and (ii) a physiologically acceptable conversion inhibitor that is capable of inhibiting the chemical conversion ex vivo of the ephedrine component into methamphetamine.
A pharmaceutical combination comprising: i) a first formulation of extended- release tramadol hydrochloride containing from 2.0% to 12.0% w/w of tramadol hydrochloride, and ii) a second formulation of immediate-release etoricoxib containing from 6.0% to 18% w/w of etoricoxib, solvents or carrier; manufacturing process to prepare the pharmaceutical combination and the individual formulations, wherein the combination is presented in a single dosage form such as, capsules, tablets, bilayer tablets, granulates and sachets. The present invention provides methods of preventing and treating pain, such as acute pain, and the use of the pharmaceutical combination for the prevention and treatment of pain, such as acute pain.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The invention relates to compounds according to general formula (I), (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A pharmaceutical combination in the bilayer tablet form of immediate release comprising: i) a first layer containing between 1.0% and 6.0% w/w of ketorolac tromethamine; ii) a second layer containing between 4.0% and 11.0% w/w of tramadol hydrochloride; and iii) an optional coating that does not modify the release of the active pharmaceutical ingredients. The present invention provides methods of preventing and treating pain, such as acute pain, and the use of the pharmaceutical combination for the prevention and treatment of pain, such as acute pain.
A61K 9/24 - Layered or laminated unitary dosage forms
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Video and audio recordings; films; compact discs; DVDs; CD ROMs; computer software and publications in electronic form (also downloadable); all the aforesaid goods relating to medical, pharmaceutical, healthcare and life-style matters. Printed matter; publications, instructional and teaching materials. Education; providing of training; arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums and workshops in the field of medical diseases, diagnostics and treatments; publication of books, texts and leaflets; production, distribution and rental of videos, films, audio recordings and compact discs, all relating to medical, pharmaceutical, healthcare and life-style matters. Scientific and technological services and research relating thereto, more specifically in the field of medical diseases, diagnostics and treatments; biological research; pharmaceutical research and development; product evaluation and drug development; design and development of computer software. Medical services; informatory, advisory and consultancy services relating to medical, pharmaceutical and healthcare matters, disease prevention and therapy.
The invention relates to a pharmaceutical composition comprising cis-(E)-4-(3-fluorophenyl)- 2',3',4',9'-tetrahydro-N,N-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1'[1H]- pyrido[3,4-b]indol]-4-amine. The pharmaceutical composition is suitable for local treatment of vulvar pain such as vulvodynia.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
The invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of said pharmacologically active compound is contained in a multitude of immediate release particles providing immediate release of the pharmacologically active compound; wherein another portion of said pharmacologically active compound is contained in at least one controlled release particle providing controlled release of the pharmacologically active compound; and wherein the breaking strength of each of the immediate release particles and/or of the at least one controlled release particle is at least 300 N.
The invention relates to 1,3-diaza-spiro-[3.4]-octane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
90.
NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
The invention relates to novel 3-indole and 3-indazole compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents. variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to novel indole and indazole compounds characterized in that the compound has general formula (I), in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 25/00 - Drugs for disorders of the nervous system
92.
MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL
The invention relates to an oral pharmaceutical dosage form comprising a plurality of coated particles, wherein said coated particles comprise a core which comprises a Tapentadol component and which is coated with a controlled release coating material, wherein the controlled release coating material comprises a lubricant component and a polymer component, wherein the polymer component comprises one or more cellulose ethers and/or one or more acrylates, and wherein the pharmaceutical dosage form provides controlled release of the Tapentadol component.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings.
The invention relates to a system for creating a medication plan for a patient, comprising: a central unit (10), which has a memory (12); a first terminal (100), which is remote from the central unit (10) and which is connected to the central unit (10) by means of the Internet (50); a second terminal (200), which is remote from the central unit (10) and which is connected to the central unit (10) by means of the Internet (50); and a third terminal (300), which is remote from the central unit (10) and which is connected to the central unit (10) by means of the Internet (50).
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
09 - Scientific and electric apparatus and instruments
Goods & Services
Application software for mobile devices for measuring, monitoring, recording, displaying and transmitting information relating to patients' health, physical activity and pain levels, to medicine intake compliance, medicine dosage tracking, wellness and healthcare instructions and therapy compliance, and for issuing reminders and motivation alerts to patients and generating reports to be shared with healthcare professionals
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates to a pharmaceutical composition comprising cis-(E)-4-(3-fluorophenyl)-2',3',4',9'-tetrahydro-N,N-dimethyl-2'-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1'[1H]- pyrido[3,4-b]indol]-4-amine. The pharmaceutical composition is suitable for topical administration, especially for intravesical administration in the treatment of bladder pain.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
99.
PHARMACEUTICAL PATCH COMPRISING LIDOCAINE AND DICLOFENAC FOR TREATING NEUROPATHIC PAIN
The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain, wherein the pain is neuropathic pain or wherein the pain has a neuropathic pain component. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
